mTOR inhibitors target the mammalian target of rapamycin and are utilized in the treatment of renal cell carcinoma (RCC), as well as for their immunosuppressive properties to prevent graft-versus-host disease following transplantation. Here, MTOR is linked to renal cell carcinoma.